Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the phase 2 GHSG NIVAHL trial
Abstract
Abstract In 82 patients with classic Hodgkin lymphoma, stable gonadal hormone levels were observed up to 24 months after nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) first-line treatment. These findings suggest preserved gonadal function and fertility after 4×N-AVD. The trial was registered at www.clinicaltrials.gov as NCT03004833.
Article Details
Authors (19)
Anne Sophie Robertz
1Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, and German Hodgkin Study Group, Cologne, Germany
Ina Bühnen
1Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, and German Hodgkin Study Group, Cologne, Germany
Julia Meissner
2Medicine V, University of Heidelberg, Heidelberg, Germany
Karolin Trautmann-Grill
3Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
Peter Herhaus
4Clinic and Policlinic for Internal Medicine III, Klinikum Rechts der Isar, School of Medicine, Technical University Munich, Munich, Germany
Teresa V. Halbsguth
5Division of Hematology/Oncology, Department of Medicine II, Goethe University Hospital Frankfurt, Frankfurt, Germany
Valdete Schaub
6Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany
Andrea Kerkhoff
7Medizinische Klinik A, University Hospital Münster, Münster, Germany
Stephan Mathas
Matthias Bormann
9Medical Department I, Klinikum Bremen-Mitte, Bremen, Germany
Andreas Dickhut
10Tumorklinik, Klinikum Fulda, Fulda, Germany
Christian P. Jaworek
1Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, and German Hodgkin Study Group, Cologne, Germany
Michael Fuchs
Carsten Kobe
11Department of Nuclear Medicine and German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany
Christian Baues
12Department of Radiation Oncology and German Hodgkin Study Group, Hospital Bochum, Bochum, Germany
Peter Borchmann
Uniklinik Koeln, Koeln, Germany
Bastian von Tresckow
1Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, and German Hodgkin Study Group, Cologne, Germany
Karolin Behringer
1Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, and German Hodgkin Study Group, Cologne, Germany
Paul J. Bröckelmann